Integra Lifesciences Holdings Corp (IART)

$29.38

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Integra Lifesciences Holdings Corp

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 380.84M → 397.03M (in $), with an average increase of 1.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 4.18M → 19.83M (in $), with an average increase of 40.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 92.8%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 70.6% return, outperforming this stock by 131.2%

Performance

  • $28.73
    $29.39
    $29.38
    downward going graph

    2.21%

    Downside

    Day's Volatility :2.25%

    Upside

    0.03%

    downward going graph
  • $27.85
    $56.41
    $29.38
    downward going graph

    5.21%

    Downside

    52 Weeks Volatility :50.63%

    Upside

    47.92%

    downward going graph

Returns

PeriodIntegra Lifesciences Holdings CorpSector (Health Care)Index (Russel 2000)
3 Months
-29.7%
1.7%
0.0%
6 Months
-16.88%
11.3%
0.0%
1 Year
-50.07%
5.4%
1.3%
3 Years
-61.54%
13.9%
-22.1%

Highlights

Market Capitalization
2.3B
Book Value
$20.31
Earnings Per Share (EPS)
0.84
PE Ratio
34.98
PEG Ratio
0.83
Wall Street Target Price
44.4
Profit Margin
4.39%
Operating Margin TTM
19.12%
Return On Assets TTM
4.24%
Return On Equity TTM
3.99%
Revenue TTM
1.5B
Revenue Per Share TTM
19.25
Quarterly Revenue Growth YOY
-0.2%
Gross Profit TTM
982.0M
EBITDA
383.6M
Diluted Eps TTM
0.84
Quarterly Earnings Growth YOY
-0.6
EPS Estimate Current Year
3.19
EPS Estimate Next Year
3.61
EPS Estimate Current Quarter
0.9
EPS Estimate Next Quarter
0.74

Analyst Recommendation

Hold
    15%Buy
    47%Hold
    36%Sell
Based on 19 Wall street analysts offering stock ratings for Integra Lifesciences Holdings Corp(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
3
3
3
Hold
9
8
9
Sell
7
8
7

Analyst Forecast

What analysts predicted

Upside of 51.12%

Current $29.38
Target $44.40

Company Financials

FY18Y/Y Change
Revenue
1.5B
↑ 23.92%
Net Income
60.8M
↓ 6.09%
Net Profit Margin
4.13%
↓ 1.32%
FY19Y/Y Change
Revenue
1.5B
↑ 3.06%
Net Income
50.2M
↓ 17.43%
Net Profit Margin
3.31%
↓ 0.82%
FY20Y/Y Change
Revenue
1.4B
↓ 9.6%
Net Income
133.9M
↑ 166.71%
Net Profit Margin
9.76%
↑ 6.45%
FY21Y/Y Change
Revenue
1.5B
↑ 12.43%
Net Income
169.1M
↑ 26.28%
Net Profit Margin
10.96%
↑ 1.2%
FY22Y/Y Change
Revenue
1.6B
↑ 0.99%
Net Income
180.6M
↑ 6.79%
Net Profit Margin
11.59%
↑ 0.63%
FY23Y/Y Change
Revenue
1.5B
↓ 1.03%
Net Income
67.7M
↓ 62.48%
Net Profit Margin
4.39%
↓ 7.2%
Q3 FY22Q/Q Change
Revenue
385.2M
↓ 3.17%
Net Income
49.9M
↑ 11.45%
Net Profit Margin
12.96%
↑ 1.7%
Q4 FY22Q/Q Change
Revenue
398.0M
↑ 3.33%
Net Income
52.9M
↑ 6.07%
Net Profit Margin
13.3%
↑ 0.34%
Q1 FY23Q/Q Change
Revenue
380.8M
↓ 4.32%
Net Income
24.2M
↓ 54.24%
Net Profit Margin
6.36%
↓ 6.94%
Q2 FY23Q/Q Change
Revenue
381.3M
↑ 0.11%
Net Income
4.2M
↓ 82.73%
Net Profit Margin
1.1%
↓ 5.26%
Q3 FY23Q/Q Change
Revenue
382.4M
↑ 0.3%
Net Income
19.5M
↑ 365.99%
Net Profit Margin
5.1%
↑ 4.0%
Q4 FY23Q/Q Change
Revenue
397.0M
↑ 3.82%
Net Income
19.8M
↑ 1.73%
Net Profit Margin
5.0%
↓ 0.1%
FY18Y/Y Change
Total Assets
3.1B
↓ 3.22%
Total Liabilities
1.7B
↓ 22.98%
FY19Y/Y Change
Total Assets
3.3B
↑ 6.29%
Total Liabilities
1.9B
↑ 8.91%
FY20Y/Y Change
Total Assets
3.6B
↑ 9.44%
Total Liabilities
2.1B
↑ 11.33%
FY21Y/Y Change
Total Assets
3.8B
↑ 4.63%
Total Liabilities
2.1B
↓ 0.13%
FY22Y/Y Change
Total Assets
3.9B
↑ 2.84%
Total Liabilities
2.1B
↓ 0.58%
FY23Y/Y Change
Total Assets
3.8B
↓ 2.77%
Total Liabilities
2.2B
↑ 5.21%
Q3 FY22Q/Q Change
Total Assets
3.8B
↑ 1.44%
Total Liabilities
2.1B
↓ 0.45%
Q4 FY22Q/Q Change
Total Assets
3.9B
↑ 2.17%
Total Liabilities
2.1B
↑ 0.13%
Q1 FY23Q/Q Change
Total Assets
3.7B
↓ 3.79%
Total Liabilities
2.1B
↓ 0.86%
Q2 FY23Q/Q Change
Total Assets
3.8B
↑ 0.94%
Total Liabilities
2.1B
↑ 1.3%
Q3 FY23Q/Q Change
Total Assets
3.7B
↓ 1.01%
Total Liabilities
2.2B
↑ 3.14%
Q4 FY23Q/Q Change
Total Assets
3.8B
↑ 1.14%
Total Liabilities
2.2B
↑ 1.57%
FY18Y/Y Change
Operating Cash Flow
199.7M
↑ 74.33%
Investing Cash Flow
-49.7M
↓ 95.93%
Financing Cash Flow
-180.9M
↓ 115.47%
FY19Y/Y Change
Operating Cash Flow
373.7M
↑ 87.14%
Investing Cash Flow
-162.7M
↑ 227.27%
Financing Cash Flow
64.5M
↓ 135.64%
FY20Y/Y Change
Operating Cash Flow
203.8M
↓ 45.45%
Investing Cash Flow
-68.1M
↓ 58.15%
Financing Cash Flow
121.6M
↑ 88.68%
FY21Y/Y Change
Operating Cash Flow
312.4M
↑ 53.28%
Investing Cash Flow
-161.4M
↑ 137.16%
Financing Cash Flow
-98.2M
↓ 180.76%
FY22Y/Y Change
Operating Cash Flow
264.5M
↓ 15.35%
Investing Cash Flow
-58.6M
↓ 63.71%
Financing Cash Flow
-252.0M
↑ 156.5%
Q3 FY22Q/Q Change
Operating Cash Flow
68.3M
↑ 2.76%
Investing Cash Flow
14.8M
↓ 429.15%
Financing Cash Flow
-7.6M
↓ 41.87%
Q4 FY22Q/Q Change
Operating Cash Flow
85.3M
↑ 24.92%
Investing Cash Flow
-54.8M
↓ 470.28%
Financing Cash Flow
-97.7M
↑ 1178.45%
Q1 FY23Q/Q Change
Operating Cash Flow
26.2M
↓ 69.35%
Investing Cash Flow
-13.7M
↓ 75.0%
Financing Cash Flow
-162.7M
↑ 66.51%
Q2 FY23Q/Q Change
Operating Cash Flow
28.3M
↑ 8.12%
Investing Cash Flow
-15.5M
↑ 13.46%
Financing Cash Flow
-10.7M
↓ 93.43%

Technicals Summary

Sell

Neutral

Buy

Integra Lifesciences Holdings Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp
-12.04%
-16.88%
-50.07%
-61.54%
-42.82%
Stryker Corporation
Stryker Corporation
-4.04%
30.03%
12.47%
26.98%
79.97%
Dexcom, Inc.
Dexcom, Inc.
-1.59%
63.45%
11.22%
31.69%
366.88%
Boston Scientific Corp.
Boston Scientific Corp.
8.35%
45.85%
42.65%
72.49%
97.43%
Abbott Laboratories
Abbott Laboratories
-2.84%
14.24%
-2.8%
-12.8%
36.85%
Medtronic Plc
Medtronic Plc
-3.44%
12.58%
-10.38%
-38.23%
-7.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp
34.98
34.98
0.83
3.19
0.04
0.04
NA
20.31
Stryker Corporation
Stryker Corporation
40.64
40.64
2.92
11.85
0.18
0.07
0.01
48.92
Dexcom, Inc.
Dexcom, Inc.
102.89
102.89
2.53
1.76
0.26
0.06
NA
5.37
Boston Scientific Corp.
Boston Scientific Corp.
64.48
64.48
1.8
2.25
0.09
0.04
NA
13.16
Abbott Laboratories
Abbott Laboratories
33.52
33.52
5.99
4.31
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.81
25.81
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Integra Lifesciences Holdings Corp
Integra Lifesciences Holdings Corp
Hold
$2.3B
-42.82%
34.98
4.39%
Stryker Corporation
Stryker Corporation
Buy
$127.4B
79.97%
40.64
15.44%
Dexcom, Inc.
Dexcom, Inc.
Buy
$54.6B
366.88%
102.89
14.95%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$101.4B
97.43%
64.48
11.18%
Abbott Laboratories
Abbott Laboratories
Buy
$186.7B
36.85%
33.52
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.9B
-7.46%
25.81
13.0%

Institutional Holdings

  • Vanguard Group Inc

    8.97%

  • BlackRock Inc

    8.49%

  • Morgan Stanley - Brokerage Accounts

    6.74%

  • Capital Research Global Investors

    5.49%

  • Wellington Management Company LLP

    4.07%

  • Cooke & Bieler LP

    3.62%

Company Information

integra lifesciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. integra's orthopedic products include devices and implants for spine, foot and ankle, hand and wrist, shoulder and elbow, tendon and peripheral nerve protection and repair, and wound repair. integra is a leader in neurosurgery, offering a broad portfolio of implants, devices, instruments and systems used in neurosurgery, neuromonitoring, neurotrauma, and related critical care. in the united states, integra is a leading provider of surgical instruments to hospitals, surgery centers and alternate care sites, including physician and dental offices. founded in 1989 integra is headquartered in plainsboro, new jersey and has over 3,500 employees worldwide. integra's common stock is li

Organization
Integra Lifesciences Holdings Corp
Employees
3946
CEO
Dr. Stuart M. Essig Ph.D.
Industry
Health Technology

Discover More

FAQs